Pap smear for men, CDC director, GLP-1s: Morning Rounds
More changes among HHS leaders
There have been some recent shuffles among top leaders at the Department of Health and Human Services (HHS). NIH Director Jay Bhattacharya will now take on the role of acting CDC director, according to an administration official who spoke to STAT’s Chelsea Cirruzzo and Anil Oza. This change comes as Jim O’Neill, the current CDC director, is set to be nominated to lead the National Science Foundation. For more details on these developments, you can read the full article.
If you’re finding it hard to keep track of the key players at HHS, Chelsea has also put together a comprehensive guide on the five individuals to watch at the department leading up to the upcoming midterms. Additionally, there’s speculation that next week’s ACIP meeting may be postponed, adding to the ongoing shifts within the department.
Decline in early prenatal care rates
New data from the National Center for Health Statistics reveals a concerning trend – the rate of pregnant individuals starting prenatal care in their first trimester has dropped from 78.3% to 75.5% between 2021 and 2024. This marks the lowest annual rate since 2016, when such data first became available. The decrease is consistent across racial and age groups, with less than half of Native Hawaiian and other Pacific Islander mothers receiving care in the first trimester.
Michael Warren, chief medical and health officer at March of Dimes, emphasized the importance of early prenatal care and expressed concerns about the U.S. moving in the wrong direction. The data underscores the need for enhanced efforts to promote timely prenatal care among expectant mothers.
Could semen analysis be the new pap smear for men?
Recent research suggests that semen analysis, traditionally used to assess fertility in men, could also serve as a valuable tool for gauging overall health. Some men’s health startups are advocating for routine semen analysis as a preventive measure against metabolic disorders, cardiovascular disease, and cancer, which have been linked to infertility and low sperm count.
While some experts support the idea of semen analysis as a screening practice for men, others remain skeptical about its widespread implementation. Paul Turek, a physician advocating for this approach, likens semen analysis to the pap smear for men. For more insights on the potential benefits and drawbacks of this screening method, check out the full article.
Patient preferences in weight loss treatment
An analysis of patient choices in weight loss treatment reveals a significant preference for GLP-1 drugs over bariatric surgery. Despite the proven efficacy of surgery in inducing weight loss and improving metabolic health, the convenience and perceived effectiveness of medication have driven a surge in GLP-1 use.
While bariatric surgeries declined by 13% in 2024, GLP-1 drug usage saw a 67% increase, reflecting a shifting trend in weight loss interventions. The cost differentials between surgery and medication also play a role in patients’ decision-making process. Elizabeth Cooney provides a detailed breakdown of the changing landscape in weight loss treatment options.
Balancing patient desires and clinical recommendations
Endocrinologist Jody Dushay reflects on the challenges of prescribing GLP-1 medications for weight loss, particularly in patients who may be at risk of developing eating disorders. She highlights the importance of addressing patients’ fixation on achieving a specific weight while overlooking their overall health improvements.
Dushay’s experiences underscore the delicate balance between patient preferences and clinical recommendations, especially in the context of weight management. Her insights shed light on the complexities of navigating patient expectations and ensuring optimal care outcomes. For more on this topic, delve into Dushay’s thoughtful essay.
